Alkermes PLC (NASDAQ:ALKS) has been assigned an average recommendation of “Hold” from the thirteen analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $62.75.

ALKS has been the topic of a number of recent analyst reports. J P Morgan Chase & Co set a $78.00 price objective on Alkermes PLC and gave the stock a “buy” rating in a research note on Thursday, April 27th. Credit Suisse Group reissued a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a research note on Wednesday, June 7th. Leerink Swann lowered Alkermes PLC from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $68.00 to $61.00 in a research note on Tuesday, June 13th. Cowen and Company reissued a “buy” rating on shares of Alkermes PLC in a research note on Friday, April 28th. Finally, ValuEngine raised Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd.

Alkermes PLC (NASDAQ ALKS) opened at 51.91 on Friday. The company’s 50-day moving average price is $56.73 and its 200 day moving average price is $57.26. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The company’s market capitalization is $7.98 billion.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The company had revenue of $218.80 million for the quarter, compared to analyst estimates of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The business’s revenue was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. On average, equities research analysts anticipate that Alkermes PLC will post ($0.04) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Alkermes PLC (ALKS) Given Average Recommendation of “Hold” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/12/alkermes-plc-alks-given-average-recommendation-of-hold-by-brokerages-2.html.

In related news, Director Richard F. Pops sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total value of $2,909,500.00. Following the completion of the sale, the director now owns 680,406 shares in the company, valued at $39,592,825.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shane Cooke sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $60.33, for a total value of $603,300.00. Following the completion of the sale, the insider now owns 84,708 shares of the company’s stock, valued at approximately $5,110,433.64. The disclosure for this sale can be found here. Insiders sold 99,500 shares of company stock valued at $5,776,365 in the last quarter. 5.34% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. FMR LLC increased its stake in shares of Alkermes PLC by 0.4% in the first quarter. FMR LLC now owns 22,882,118 shares of the company’s stock valued at $1,338,604,000 after buying an additional 86,546 shares during the period. Creative Planning increased its stake in shares of Alkermes PLC by 16.2% in the first quarter. Creative Planning now owns 18,012 shares of the company’s stock valued at $1,054,000 after buying an additional 2,510 shares during the period. Sei Investments Co. increased its stake in shares of Alkermes PLC by 32.6% in the first quarter. Sei Investments Co. now owns 90,325 shares of the company’s stock valued at $5,284,000 after buying an additional 22,228 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in shares of Alkermes PLC by 4.8% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 17,505 shares of the company’s stock valued at $1,024,000 after buying an additional 795 shares during the period. Finally, Capstone Asset Management Co. increased its stake in shares of Alkermes PLC by 8.0% in the first quarter. Capstone Asset Management Co. now owns 6,585 shares of the company’s stock valued at $385,000 after buying an additional 490 shares during the period. Institutional investors own 97.41% of the company’s stock.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Analyst Recommendations for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.